Please login to the form below

Not currently logged in
Email:
Password:

Report reveals concern over EU pharma acquisition debt

A report from Moody's Investor Service has revealed that EU drug companies will find it difficult to maintain high credit ratings in the long term over increasingly aggressive acquisition strategies to shore up flagging pipelines and combating generic erosion of profits

A report from Moody's Investor Service has revealed that European drug companies will find it difficult to maintain high credit ratings in the long term over increasingly aggressive acquisition strategies to shore up flagging pipelines and combating generic erosion of profits.

The report highlights a shift toward financing acquisitions through debt, which could bring down the industry's rating. The new strategy differs from the large mergers of the 1990s, which were all-share transactions and thus did not affect analyst ratings.

AstraZeneca (AZ) is cited as an example, with the company running up increased debt in April 2007, when it bought US biotech company MedImmune for USD 15.6bn. Consequently, AZ's debt is expected to increase to USD 7.7bn by the end of 2007, compared with net cash of USD 6.5bn at the end of 2006.

Also mentioned is UK pharmaceutical company Shire, which has issued convertible bonds to refinance some of the bank facilities it used for the USD 2.6bn buyout of US-headquartered New River Pharmaceuticals.

The report advised that pharmaceutical companies could use asset disposals to help mitigate debt incurred in acquisitions, as exemplified by Novartis' sale of its nutrition business to help rebuild its financial flexibility, after acquisitions had augmented the size of its vaccines and generics units. Merck KGaA sold its generics unit for EUR 4.9bn (USD 6.7bn) in May 2007, to reduce the debt resulting from its purchase of Swiss biotech Serono.

Moody's senior vice-president Jean-Michel Carayon said: "The recent increase in the valuation of biotechnology companies, and the growing interest from traditional pharmaceutical companies in biotechnology, contribute to potential sizable acquisitions, which may result in increased leverage for some of the rated companies."

11th July 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics